What is the purpose of this trial?
Assessment of the safety and tolerability of a single administration of 3 mega Becquerel (MBq)/kg, but not less than 150 MBq and not more than 250 MBq, of 68Ga-PSMA-R2, to assess the pharmacokinetics (PK), biodistribution, and dosimetry of 68Ga-PSMA-R2, and to establish the optimal imaging method for determining location and burden of positive lesions in adult male patients with biochemical relapse (BR) and metastatic prostate cancer (mPCa).
Ages: 18 years and older
Gender: Male only
Advanced Accelerator Applications International SA
Start Date: 03/04/2019
End Date: 06/03/2019
Last Updated: 04/25/2019
Study HIC#: 2000023359